Overton nominated to lead FDA with the compounding dockets on the desk

President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, to serve as FDA commissioner on August 19, 2026. She is his third choice for the post: acting commissioner Kyle Diamantas and former Representative Brad Wenstrup of Ohio both declined the job before her name surfaced.^[1]

Overton has not made any public statements on peptide compounding, the 503A or 503B bulk drug substance lists, or GLP-1 policy generally, according to the tracker of FDA actions compiled by PeptidesBeat.^[1] No confirmation hearing date has been set. Senate HELP Committee chair Bill Cassidy has said her record "alone is almost disqualifying."^[1]

The timing matters because several unresolved GLP-1 and peptide dockets will land on whoever ends up running the agency, confirmed or acting. One is the 503A Bulks List rulemaking: a Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026, recommended six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the list, but that vote is nonbinding, and formal rulemaking can take up to a year, meaning none of the six is lawfully compoundable today.^[1] A second is a proposal from April 30, 2026, to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which remains undecided.^[1]

Separately, on August 27, 2026, the Fifth Circuit Court of Appeals upheld the FDA's removal of semaglutide and tirzepatide from the federal drug shortage list, ending bulk compounding of those molecules for general use while leaving patient-specific compounding for an individual with a documented medical need legal.^[1] The same week the nomination was announced, Novo Nordisk formally asked the FDA to add semaglutide to the Demonstrable Difficulties for Compounding list — a request first filed in October 2024 — joining Eli Lilly's parallel push to bar GLP-1 compounding altogether.^[1]

Why it matters for patients

For people currently taking FDA-approved semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), the leadership vacancy does not change access to those products. But for patients who rely on compounded versions, the rules that determine what is legal are still being written, and the person who will finally decide them has not said anything publicly about the issue.^[1]

Patient-specific 503A compounding for someone with a documented medical need remains legal after the Fifth Circuit ruling, but bulk compounding of semaglutide and tirzepatide for general use is not.^[1] Whether peptides like BPC-157 or TB-500 ever become legal to compound depends on a rulemaking process that has no announced timeline, and whether GLP-1 compounding gets an additional formal ban depends on a 503B exclusion decision and a pending industry petition that also have no resolution date.^[1] All of that now depends on when — or whether — the Senate confirms a new commissioner.

What happens next

No Senate hearing date has been scheduled for Overton as of this writing.^[1] The 503A Bulks List rulemaking and the 503B GLP-1 exclusion proposal both remain open, with FDA having set no public timeline for either.^[1] Enforcement continues in parallel: FDA posted five warning letters on September 1, 2026, to online sellers of unapproved injectable peptides, a track separate from the compounding rulemaking but part of the same broader crackdown.^[1]